{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:43:50Z","timestamp":1788349430908,"version":"build-2803163510"},"reference-count":173,"publisher":"Bentham Science Publishers Ltd.","issue":"11","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Drug repositioning is a strategy to identify new uses for approved or investigational\ndrugs that are used off-label outside the scope of the original medical indication.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>In this review, we report the most relevant studies about drug repositioning in hematology,\nreporting the signalling pathways and molecular targets of these drugs, and describing the biological\nmechanisms which are responsible for their anticancer effects.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Although the majority of studies on drug repositioning in hematology concern acute myeloid\nleukemia and multiple myeloma, numerous studies are present in the literature on the possibility\nof using these drugs also in other hematological diseases, such as acute lymphoblastic leukemia,\nchronic myeloid leukemia, and lymphomas. Numerous anti-infectious drugs and\nchemical entities used for the therapy of neurological or endocrine diseases, oral antidiabetics,\nstatins and medications used to treat high blood pressure and heart failure, bisphosphonate\nand natural substance such as artemisin and curcumin, have found a place in the treatment of\nhematological diseases. Moreover, several molecules drastically reversed the resistance of the\ntumor cells to the chemotherapeutic drugs both in vitro and in vivo.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867327999200817102154","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T07:32:26Z","timestamp":1597822346000},"page":"2195-2217","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Drug Repositioning for the Treatment of Hematologic Disease: Limits, Challenges and Future Perspectives"],"prefix":"10.2174","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-8239","authenticated-orcid":true,"given":"Alessandro","family":"Allegra","sequence":"first","affiliation":[{"name":"Department of Human Pathology in Adulthood and Childhood, University of Messina, Messina,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-1427-2312","authenticated-orcid":true,"given":"Chiara","family":"Imbesi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, Messina,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9300-7532","authenticated-orcid":true,"given":"Alessandra","family":"Bitto","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, Messina,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9020-2068","authenticated-orcid":true,"given":"Roberta","family":"Ettari","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Chemistry, University of Messina, Messina,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"Ashburn T.T.","year":"2004","unstructured":"Ashburn T.T.; Thor K.B.; Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004,3(8),673-683","journal-title":"Nat Rev Drug Discov"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"Pushpakom S.","year":"2019","unstructured":"Pushpakom S.; Iorio F.; Eyers P.A.; Escott K.J.; Hopper S.; Wells A.; Doig A.; Guilliams T.; Latimer J.; McNamee C.; Norris A.; Sanseau P.; Cavalla D.; Pirmohamed M.; Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 2019,18(1),41-58","journal-title":"Nat Rev Drug Discov"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.2174\/1381612822666160224143008","volume":"22","author":"Haupt V.J.","year":"2016","unstructured":"Haupt V.J.; Aguilar Uvalle J.E.; Salentin S.; Daminelli S.; Leonhardt F.; Konc J.; Schroeder M.; Computational drug repositioning by target hopping: a use case in Chagas disease drug repositioning by target hopping. Curr Pharm Des 2016,22(21),3124-3134","journal-title":"Curr Pharm Des"},{"key":"ref=4","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv315","volume":"43","author":"Salentin S.","year":"2015","unstructured":"Salentin S.; Schreiber S.; Haupt V.J.; Adasme M.F.; Schroeder M.; PLIP: fully automated protein-ligand interaction profiler. Nucleic Acids Res 2015,43(W1)","journal-title":"Nucleic Acids Res"},{"key":"ref=5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172784","author":"Antoszczak M.","year":"2020","unstructured":"Antoszczak M.; Markowska A.; Markowska J.; Huczy\u0144ski A.; Old wine in new bottles: drug repurposing in oncology. Eur J Pharmacol 2020","journal-title":"Eur J Pharmacol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12967-016-1007-5","volume":"14","author":"Lara-Castillo M.C.","year":"2016","unstructured":"Lara-Castillo M.C.; Cornet-Masana J.M.; Etxabe A.; Ban\u00fas-Mulet A.; Torrente M.A.; Nomdedeu M.; D\u00edaz-Bey\u00e1 M.; Esteve J.; Risue\u00f1o R.M.; Repositioning of bromocriptine for treatment of acute myeloid leukemia. J Transl Med 2016,14(1),261","journal-title":"J Transl Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1038\/leu.2017.52","volume":"31","author":"Etxabe A.","year":"2017","unstructured":"Etxabe A.; Lara-Castillo M.C.; Cornet-Masana J.M.; Ban\u00fas-Mulet A.; Nomdedeu M.; Torrente M.A.; Pratcorona M.; D\u00edaz-Bey\u00e1 M.; Esteve J.; Risue\u00f1o R.M.; Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem cell functionality: a promising novel therapeutic target. Leukemia 2017,31(11),2288-2302","journal-title":"Leukemia"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2012.03.049","volume":"149","author":"Sachlos E.","year":"2012","unstructured":"Sachlos E.; Risue\u00f1o R.M.; Laronde S.; Shapovalova Z.; Lee J-H.; Russell J.; Malig M.; McNicol J.D.; Fiebig-Comyn A.; Graham M.; Levadoux-Martin M.; Lee J.B.; Giacomelli A.O.; Hassell J.A.; Fischer-Russell D.; Trus M.R.; Foley R.; Leber B.; Xenocostas A.; Brown E.D.; Collins T.J.; Bhatia M.; Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012,149(6),1284-1297","journal-title":"Cell"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"6609","DOI":"10.18632\/oncotarget.6773","volume":"7","author":"Liberante F.G.","year":"2016","unstructured":"Liberante F.G.; Pouryahya T.; McMullin M.F.; Zhang S.D.; Mills K.I.; Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Oncotarget 2016,7(6),6609-6619","journal-title":"Oncotarget"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1111\/febs.15102]","volume":"287","author":"Du Y.","year":"2020","unstructured":"Du Y.; Li K.; Wang X.; Kaushik A.C.; Junaid M.; Wei D.; Identification of chlorprothixene as a potential drug that induces apoptosis and autophagic cell death in acute myeloid leukemia cells. FEBS J 2020,287(8),1645-1665","journal-title":"FEBS J"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1182\/blood-2009-09-243055","volume":"115","author":"Spagnuolo P.A.","year":"2010","unstructured":"Spagnuolo P.A.; Hu J.; Hurren R.; Wang X.; Gronda M.; Sukhai M.A.; Di Meo A.; Boss J.; Ashali I.; Beheshti Zavareh R.; Fine N.; Simpson C.D.; Sharmeen S.; Rottapel R.; Schimmer A.D.; The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood 2010,115(23),4824-4833","journal-title":"Blood"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1007\/s00432-013-1539-5","volume":"139","author":"Nygren P.","year":"2013","unstructured":"Nygren P.; Frykn\u00e4s M.; \u00c5gerup B.; Larsson R.; Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. J Cancer Res Clin Oncol 2013,139(12),2133-2140","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1478-811X-9-13","volume":"9","author":"Ehsanian R.","year":"2011","unstructured":"Ehsanian R.; Van Waes C.; Feller S.M.; Beyond DNA binding - a review of the potential mechanisms mediating quinacrine\u2019s therapeutic activities in parasitic infections, inflammation, and cancers. Cell Commun Signal 2011,9,13","journal-title":"Cell Commun Signal"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"17448","DOI":"10.1073\/pnas.0508888102","volume":"102","author":"Gurova K.V.","year":"2005","unstructured":"Gurova K.V.; Hill J.E.; Guo C.; Prokvolit A.; Burdelya L.G.; Samoylova E.; Khodyakova A.V.; Ganapathi R.; Ganapathi M.; Tararova N.D.; Bosykh D.; Lvovskiy D.; Webb T.R.; Stark G.R.; Gudkov A.V.; Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 2005,102(48),17448-17453","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=15","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.31","volume":"5","author":"Eriksson A.","year":"2015","unstructured":"Eriksson A.; \u00d6sterroos A.; Hassan S.; Gullbo J.; Rickardson L.; Jarvius M.; Nygren P.; Frykn\u00e4s M.; H\u00f6glund M.; Larsson R.; Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia. Blood Cancer J 2015,5(4)","journal-title":"Blood Cancer J"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1182\/blood.V98.8.2301","volume":"98","author":"Guzman M.L.","year":"2001","unstructured":"Guzman M.L.; Neering S.J.; Upchurch D.; Grimes B.; Howard D.S.; Rizzieri D.A.; Luger S.M.; Jordan C.T.; Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001,98(8),2301-2307","journal-title":"Blood"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.bcp.2006.06.011","volume":"72","author":"Keutgens A.","year":"2006","unstructured":"Keutgens A.; Robert I.; Viatour P.; Chariot A.; Deregulated NF-kappaB activity in haematological malignancies. Biochem Pharmacol 2006,72(9),1069-1080","journal-title":"Biochem Pharmacol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.leukres.2017.10.012","volume":"63","author":"Eriksson A.","year":"2017","unstructured":"Eriksson A.; Chantzi E.; Frykn\u00e4s M.; Gullbo J.; Nygren P.; Gustafsson M.; H\u00f6glund M.; Larsson R.; Towards repositioning of quinacrine for treatment of acute myeloid leukemia - promising synergies and in vivo effects. Leuk Res 2017,63,41-46","journal-title":"Leuk Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1023\/A:1006333608012","volume":"23","author":"Ali B.H.","year":"1999","unstructured":"Ali B.H.; Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. Vet Res Commun 1999,23(6),343-360","journal-title":"Vet Res Commun"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4103\/1319-3767.91729","volume":"18","author":"Zullo A.","year":"2012","unstructured":"Zullo A.; Ierardi E.; Hassan C.; De Francesco V.; Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis. Saudi J Gastroenterol 2012,18(1),11-17","journal-title":"Saudi J Gastroenterol"},{"key":"ref=21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072335","volume":"8","author":"Jiang X.","year":"2013","unstructured":"Jiang X.; Sun L.; Qiu J.J.; Sun X.; Li S.; Wang X.; So C.W.; Dong S.; A novel application of furazolidone: anti-leukemic activity in acute myeloid leukemia. PLoS One 2013,8(8)","journal-title":"PLoS One"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1748-1716.2011.02273.x","volume":"204","author":"Insel P.A.","year":"2012","unstructured":"Insel P.A.; Zhang L.; Murray F.; Yokouchi H.; Zambon A.C.; Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger. Acta Physiol (Oxf) 2012,204(2),277-287","journal-title":"Acta Physiol (Oxf)"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1085\/jgp.201311083","volume":"143","author":"Conti M.","year":"2014","unstructured":"Conti M.; Mika D.; Richter W.; Cyclic AMP compartments and signaling specificity: role of cyclic nucleotide phosphodiesterases. J Gen Physiol 2014,143(1),29-38","journal-title":"J Gen Physiol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"33960","DOI":"10.18632\/oncotarget.8986","volume":"7","author":"Perez D.R.","year":"2016","unstructured":"Perez D.R.; Smagley Y.; Garcia M.; Carter M.B.; Evangelisti A.; Matlawska-Wasowska K.; Winter S.S.; Sklar L.A.; Chigaev A.; Cyclic AMP efflux inhibitors as potential therapeutic agents for leukemia. Oncotarget 2016,7(23),33960-33982","journal-title":"Oncotarget"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.bbrc.2018.10.053","volume":"506","author":"Yonezawa H.","year":"2018","unstructured":"Yonezawa H.; Ogawa M.; Katayama, S.; Shimizu, Y.; Omori, N.; Oku, Y.; Sakyo, T.; Uehara, Y.; Nishiya, N. Clotrimazole inhibits the Wnt\/b-catenin pathway by activating two eIF2a kinases: The heme-regulated translational inhibitor and the double-stranded RNA-induced protein kinase. Biochem Biophys Res Commun 2018,506(1),183-188","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.leukres.2016.08.002","volume":"49","author":"Allegra A.","year":"2016","unstructured":"Allegra A.; Innao V.; Gerace D.; Bianco O.; Musolino C.; The metabolomic signature of hematologic malignancies. Leuk Res 2016,49,22-35","journal-title":"Leuk Res"},{"key":"ref=27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084369","volume":"9","author":"Nangia-Makker P.","year":"2014","unstructured":"Nangia-Makker P.; Yu Y.; Vasudevan A.; Farhana L.; Rajendra S.G.; Levi E.; Majumdar A.P.; Metformin: a potential therapeutic agent for recurrent colon cancer. PLoS One 2014,9(1)","journal-title":"PLoS One"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11934-017-0693-8","volume":"18","author":"Whitburn J.","year":"2017","unstructured":"Whitburn J.; Edwards C.M.; Sooriakumaran P.; Metformin and prostate cancer: a new role for an old drug. Curr Urol Rep 2017,18(6),46","journal-title":"Curr Urol Rep"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1182\/blood-2002-12-3813","volume":"102","author":"Minami Y.","year":"2003","unstructured":"Minami Y.; Yamamoto K.; Kiyoi H.; Ueda R.; Saito H.; Naoe T.; Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. Blood 2003,102(8),2969-2975","journal-title":"Blood"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/sj.leu.2402945","volume":"17","author":"Chang F.","year":"2003","unstructured":"Chang F.; Steelman L.S.; Lee J.T.; Shelton J.G.; Navolanic P.M.; Blalock W.L.; Franklin R.A.; McCubrey J.A.; Signal transduction mediated by the Ras\/Raf\/MEK\/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003,17(7),1263-1293","journal-title":"Leukemia"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.leukres.2016.10.004","volume":"50","author":"Sabnis H.S.","year":"2016","unstructured":"Sabnis H.S.; Bradley H.L.; Tripathi S.; Yu W.M.; Tse W.; Qu C.K.; Bunting K.D.; Synergistic cell death in FLT3-ITD positive acute myeloid leukemia by combined treatment with metformin and 6-benzylthioinosine. Leuk Res 2016,50,132-140","journal-title":"Leuk Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.leukres.2015.09.016","volume":"39","author":"Wang F.","year":"2015","unstructured":"Wang F.; Liu Z.; Zeng J.; Zhu H.; Li J.; Cheng X.; Jiang T.; Zhang L.; Zhang C.; Chen T.; Liu T.; Jia Y.; Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy. Leuk Res 2015,39(12),1421-1427","journal-title":"Leuk Res"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0014-2999(99)00122-3","volume":"370","author":"Buemi M.","year":"1999","unstructured":"Buemi M.; Allegra A.; Senatore M.; Marino D.; Medici M.A.; Aloisi C.; Di Pasquale G.; Corica F.; Pro-apoptotic effect of fluvastatin on human smooth muscle cells. Eur J Pharmacol 1999,370(2),201-203","journal-title":"Eur J Pharmacol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"5859","DOI":"10.1007\/s11033-019-05019-8","volume":"46","author":"Jang J.","year":"2019","unstructured":"Jang J.; Lee J.; Jang J.H.; Jung C.W.; Park S.; Anti-leukemic effects of simvastatin on NRASG12D mutant acute myeloid leukemia cells. Mol Biol Rep 2019,46(6),5859-5866","journal-title":"Mol Biol Rep"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.leukres.2018.01.021","volume":"67","author":"Advani A.S.","year":"2018","unstructured":"Advani A.S.; Li H.; Michaelis L.C.; Medeiros B.C.; Liedtke M.; List A.F.; O\u2019Dwyer K.; Othus M.; Erba H.P.; Appelbaum F.R.; Report of the relapsed\/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). Leuk Res 2018,67,17-20","journal-title":"Leuk Res"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/ajh.23981","volume":"90","author":"Shadman M.","year":"2015","unstructured":"Shadman M.; Mawad R.; Dean C.; Chen T.L.; Shannon-Dorcy K.; Sandhu V.; Hendrie P.C.; Scott B.L.; Walter R.B.; Becker P.S.; Pagel J.M.; Estey E.H.; Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome. Am J Hematol 2015,90(6),483-486","journal-title":"Am J Hematol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","volume":"3","author":"Pemovska T.","year":"2013","unstructured":"Pemovska T.; Kontro M.; Yadav B.; Edgren H.; Eldfors S.; Szwajda A.; Almusa H.; Bespalov M.M.; Ellonen P.; Elonen E.; Gjertsen B.T.; Karjalainen R.; Kulesskiy E.; Lagstr\u00f6m S.; Lehto A.; Lepist\u00f6 M.; Lund\u00e1n T.; Majumder M.M.; Marti J.M.; Mattila P.; Murum\u00e4gi A.; Mustjoki S.; Palva A.; Parsons A.; Pirttinen T.; R\u00e4met M.E.; Suvela M.; Turunen L.; V\u00e4strik I.; Wolf M.; Knowles J.; Aittokallio T.; Heckman C.A.; Porkka K.; Kallioniemi O.; Wennerberg K.; Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov 2013,3(12),1416-1429","journal-title":"Cancer Discov"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1093\/jnci\/88.18.1276","volume":"88","author":"Sredni B.","year":"1996","unstructured":"Sredni B.; Tichler T.; Shani A.; Catane R.; Kaufman B.; Strassmann G.; Albeck M.; Kalechman Y.; Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101. J Natl Cancer Inst 1996,88(18),1276-1284","journal-title":"J Natl Cancer Inst"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1096\/fj.03-0552fje","volume":"18","author":"Sredni B.","year":"2004","unstructured":"Sredni B.; Gal R.; Cohen I.J.; Dazard J.E.; Givol D.; Gafter U.; Motro B.; Eliyahu S.; Albeck M.; Lander H.M.; Kalechman Y.; Hair growth induction by the Tellurium immunomodulator AS101: association with delayed terminal differentiation of follicular keratinocytes and RAS-dependent up-regulation of KGF expression. FASEB J 2004,18(2),400-402","journal-title":"FASEB J"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1158\/0008-5472.CAN-03-3179","volume":"64","author":"Sredni B.","year":"2004","unstructured":"Sredni B.; Weil M.; Khomenok G.; Lebenthal I.; Teitz S.; Mardor Y.; Ram Z.; Orenstein A.; Kershenovich A.; Michowiz S.; Cohen Y.I.; Rappaport Z.H.; Freidkin I.; Albeck M.; Longo D.L.; Kalechman Y.; Ammonium trichloro(dioxoethylene-o,o\u2032)tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res 2004,64(5),1843-1852","journal-title":"Cancer Res"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"36984","DOI":"10.1074\/jbc.M003279200","volume":"275","author":"O\u2019Neill S.","year":"2000","unstructured":"O\u2019Neill S.; Robinson A.; Deering A.; Ryan M.; Fitzgerald D.J.; Moran N.; The platelet integrin alpha IIbbeta 3 has an endogenous thiol isomerase activity. J Biol Chem 2000,275(47),36984-36990","journal-title":"J Biol Chem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1096\/fj.06-7500com","volume":"21","author":"Sredni B.","year":"2007","unstructured":"Sredni B.; Geffen-Aricha R.; Duan W.; Albeck M.; Shalit F.; Lander H.M.; Kinor N.; Sagi O.; Albeck A.; Yosef S.; Brodsky M.; Sredni-Kenigsbuch D.; Sonino T.; Longo D.L.; Mattson M.P.; Yadid G.; Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson\u2019s disease models. FASEB J 2007,21(8),1870-1883","journal-title":"FASEB J"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"32435","DOI":"10.1074\/jbc.M404387200","volume":"279","author":"Chigaev A.","year":"2004","unstructured":"Chigaev A.; Zwartz G.J.; Buranda T.; Edwards B.S.; Prossnitz E.R.; Sklar L.A.; Conformational regulation of alpha 4 beta 1-integrin affinity by reducing agents. \u201cInside-out\u201d signaling is independent of and additive to reduction-regulated integrin activation. J Biol Chem 2004,279(31),32435-32443","journal-title":"J Biol Chem"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"8861","DOI":"10.1021\/bi002902i","volume":"40","author":"Yan B.","year":"2001","unstructured":"Yan B.; Smith J.W.; Mechanism of integrin activation by disulfide bond reduction. Biochemistry 2001,40(30),8861-8867","journal-title":"Biochemistry"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1158\/0008-5472.CAN-13-2159","volume":"74","author":"Layani-Bazar A.","year":"2014","unstructured":"Layani-Bazar A.; Skornick I.; Berrebi A.; Pauker M.H.; Noy E.; Silberman A.; Albeck M.; Longo D.L.; Kalechman Y.; Sredni B.; Redox modulation of adjacent thiols in VLA-4 by AS101 converts myeloid leukemia cells from a drug-resistant to drug-sensitive state. Cancer Res 2014,74(11),3092-3103","journal-title":"Cancer Res"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMoa1706854","volume":"379","author":"King C.L.","year":"2018","unstructured":"King C.L.; Suamani J.; Sanuku N.; Cheng Y.C.; Satofan S.; Mancuso B.; Goss C.W.; Robinson L.J.; Siba P.M.; Weil G.J.; Kazura J.W.; A trial of a triple-drug treatment for lymphatic filariasis. N Engl J Med 2018,379(19),1801-1810","journal-title":"N Engl J Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.15252\/emmm.201404084","volume":"6","author":"Melotti A.","year":"2014","unstructured":"Melotti A.; Mas C.; Kuciak M.; Lorente-Trigos A.; Borges I.; Ruiz i Altaba A.; The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer. EMBO Mol Med 2014,6(10),1263-1278","journal-title":"EMBO Mol Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1158\/0008-5472.CAN-15-2887","volume":"76","author":"Dou Q.","year":"2016","unstructured":"Dou Q.; Chen H.N.; Wang K.; Yuan K.; Lei Y.; Li K.; Lan J.; Chen Y.; Huang Z.; Xie N.; Zhang L.; Xiang R.; Nice E.C.; Wei Y.; Huang C.; Ivermectin induces cytostatic autophagy by blocking the PAK1\/Akt axis in breast cancer. Cancer Res 2016,76(15),4457-4469","journal-title":"Cancer Res"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejps.2006.10.004","volume":"30","author":"Lespine A.","year":"2007","unstructured":"Lespine A.; Martin S.; Dupuy J.; Roulet A.; Pineau T.; Orlowski S.; Alvinerie M.; Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship. Eur J Pharm Sci 2007,30(1),84-94","journal-title":"Eur J Pharm Sci"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cbi.2005.11.002","volume":"159","author":"Lespine A.","year":"2006","unstructured":"Lespine A.; Dupuy J.; Orlowski S.; Nagy T.; Glavinas H.; Krajcsi P.; Alvinerie M.; Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3). Chem Biol Interact 2006,159(3),169-179","journal-title":"Chem Biol Interact"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejphar.2004.03.067","volume":"493","author":"Korystov Y.N.","year":"2004","unstructured":"Korystov Y.N.; Ermakova N.V.; Kublik L.N.; Levitman M.Kh.; Shaposhnikova V.V.; Mosin V.A.; Drinyaev V.A.; Kruglyak E.B.; Novik T.S.; Sterlina T.S.; Avermectins inhibit multidrug resistance of tumor cells. Eur J Pharmacol 2004,493(1-3),57-64","journal-title":"Eur J Pharmacol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13046-019-1251-7","volume":"38","author":"Jiang L.","year":"2019","unstructured":"Jiang L.; Wang P.; Sun Y.J.; Wu Y.J.; Ivermectin reverses the drug resistance in cancer cells through EGFR\/ERK\/Akt\/NF-\u03baB pathway. J Exp Clin Cancer Res 2019,38(1),265","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1517\/13543776.2013.743995","volume":"23","author":"Xu S.","year":"2013","unstructured":"Xu S.; Liu P.; Tanshinone II-A: new perspectives for old remedies. Expert Opin Ther Pat 2013,23(2),149-153","journal-title":"Expert Opin Ther Pat"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1039\/c0np00035c","volume":"28","author":"Dong Y.","year":"2011","unstructured":"Dong Y.; Morris-Natschke S.L.; Lee K.H.; Biosynthesis, total syntheses, and antitumor activity of tanshinones and their analogs as potential therapeutic agents. Nat Prod Rep 2011,28(3),529-542","journal-title":"Nat Prod Rep"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1002\/pmic.201300274","volume":"13","author":"Pan T.L.","year":"2013","unstructured":"Pan T.L.; Wang P.W.; Hung Y.C.; Huang C.H.; Rau K.M.; Proteomic analysis reveals tanshinone IIA enhances apoptosis of advanced cervix carcinoma CaSki cells through mitochondria intrinsic and endoplasmic reticulum stress pathways. Proteomics 2013,13(23-24),3411-3423","journal-title":"Proteomics"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/aps.2009.139","volume":"30","author":"Shan Y.F.","year":"2009","unstructured":"Shan Y.F.; Shen X.; Xie Y.K.; Chen J.C.; Shi H.Q.; Yu Z.P.; Song Q.T.; Zhou M.T.; Zhang Q.Y.; Inhibitory effects of tanshinone II-A on invasion and metastasis of human colon carcinoma cells. Acta Pharmacol Sin 2009,30(11),1537-1542","journal-title":"Acta Pharmacol Sin"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.7314\/APJCP.2012.13.9.4453","volume":"13","author":"Zhou L.H.","year":"2012","unstructured":"Zhou L.H.; Hu Q.; Sui H.; Ci S.J.; Wang Y.; Liu X.; Liu N.N.; Yin P.H.; Qin J.M.; Li Q.; Tanshinone II--a inhibits angiogenesis through down regulation of COX-2 in human colorectal cancer. Asian Pac J Cancer Prev 2012,13(9),4453-4458","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref=58","first-page":"163","volume":"38","author":"Zhai X.M.","year":"2009","unstructured":"Zhai X.M.; He S.X.; Ren M.D.; Chen J.H.; Wang Z.L.; Han M.; Hou H.L.;  [Effect of Tanshinone II A on expression of EGF and EGFR in hepatocellular carcinoma cell line SMMC-7721]. Zhejiang Da Xue Xue Bao Yi Xue Ban2009,38(2),163-169"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1002\/jcb.24553","volume":"114","author":"Lin C.","year":"2013","unstructured":"Lin C.; Wang L.; Wang H.; Yang L.; Guo H.; Wang X.; Tanshinone IIA inhibits breast cancer stem cells growth in vitro and in vivo through attenuation of IL-6\/STAT3\/NF-kB signaling pathways. J Cell Biochem 2013,114(9),2061-2070","journal-title":"J Cell Biochem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.7314\/APJCP.2014.15.10.4301","volume":"15","author":"Chen S-J.","year":"2014","unstructured":"Chen S-J.; A potential target of Tanshinone IIA for acute promyelocytic leukemia revealed by inverse docking and drug repurposing. Asian Pac J Cancer Prev 2014,15(10),4301-4305","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrc2943","volume":"10","author":"de Th\u00e9 H.","year":"2010","unstructured":"de Th\u00e9 H.; Chen Z.; Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010,10(11),775-783","journal-title":"Nat Rev Cancer"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1073\/pnas.0712365105","volume":"105","author":"Wang L.","year":"2008","unstructured":"Wang L.; Zhou G.B.; Liu P.; Song J.H.; Liang Y.; Yan X.J.; Xu F.; Wang B.S.; Mao J.H.; Shen Z.X.; Chen S.J.; Chen Z.; Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA 2008,105(12),4826-4831","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/leu.2010.95","volume":"24","author":"Marstrand T.T.","year":"2010","unstructured":"Marstrand T.T.; Borup R.; Willer A.; Borregaard N.; Sandelin A.; Porse B.T.; Theilgaard-M\u00f6nch K.; A conceptual framework for the identification of candidate drugs and drug targets in acute promyelocytic leukemia. Leukemia 2010,24(7),1265-1275","journal-title":"Leukemia"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ajh.21352","volume":"84","author":"Kasner M.T.","year":"2009","unstructured":"Kasner M.T.; Luger S.M.; Update on the therapy for myelodysplastic syndrome. Am J Hematol 2009,84(3),177-186","journal-title":"Am J Hematol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1600-0609.2010.01433.x","volume":"84","author":"Musolino C.","year":"2010","unstructured":"Musolino C.; Sant\u2019antonio E.; Penna G.; Alonci A.; Russo S.; Granata A.; Allegra A.; Epigenetic therapy in myelodysplastic syndromes. Eur J Haematol 2010,84(6),463-473","journal-title":"Eur J Haematol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S0145-2126(09)70226-7","volume":"33","author":"Gore S.D.","year":"2009","unstructured":"Gore S.D.; In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment? Leuk Res 2009,33(Suppl. 2),S2-S6","journal-title":"Leuk Res"},{"key":"ref=67","first-page":"1596","volume":"9","author":"Segura-Pacheco B.","year":"2003","unstructured":"Segura-Pacheco B.; Trejo-Becerril C.; P\u00e9rez-C\u00e1rdenas E.; Taja-Chayeb L.; Mariscal I.; Chavez A.; Acu\u00f1a C.; Salazar A.M.; Lizano M.; Due\u00f1as-Gonzalez A.; Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res 2003,9(5),1596-1603","journal-title":"Clin Cancer Res"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1471-2407-5-44","volume":"5","author":"Zambrano P.","year":"2005","unstructured":"Zambrano P.; Segura-Pacheco B.; P\u00e9rez-C\u00e1rdenas E.; Cetina L.; Revilla-Vazquez A.; Taja-Chayeb L.; Chavez-Blanco A.; Angeles E.; Cabrera G.; Sandoval K.; Trejo-Becerril C.; Chanona-Vilchis J.; Duenas-Gonz\u00e1lez A.; A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer 2005,5,44","journal-title":"BMC Cancer"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10330-008-0119-7","volume":"7","author":"Li H.","year":"2008","unstructured":"Li H.; Chen S.; Shu Y.; Chen Y.; Su Y.; Wang X.; Zou S.; Synergy of DNA methylation and histone deacetylase inhibitors in the re-expression of RASSF1A and P16 genes silenced in QBC cells. Chinese-German J Clin Oncol 2008,7,627-630","journal-title":"Chinese-German J Clin Oncol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11684-009-0034-5","volume":"3","author":"Li H.","year":"2009","unstructured":"Li H.; Chen S.; Shu Y.; Chen Y.; Su Y.; Wang X.; Zou S.; Effects of hydralazine and valproate on the expression of E-cadherin gene and the invasiveness and the invasiveness of QBC939 cells. Front Med China 2009,3,153-157","journal-title":"Front Med China"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/annonc\/mdm204","volume":"18","author":"Candelaria M.","year":"2007","unstructured":"Candelaria M.; Gallardo-Rinc\u00f3n D.; Arce C.; Cetina L.; Aguilar-Ponce J.L.; Arrieta O.; Gonz\u00e1lez-Fierro A.; Ch\u00e1vez-Blanco A.; de la Cruz-Hern\u00e1ndez E.; Camargo M.F.; Trejo-Becerril C.; P\u00e9rez-C\u00e1rdenas E.; P\u00e9rez-Plasencia C.; Taja-Chayeb L.; Wegman-Ostrosky T.; Revilla-Vazquez A.; Due\u00f1as-Gonz\u00e1lez A.; A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 2007,18(9),1529-1538","journal-title":"Ann Oncol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"G\u00f6ttlicher M.","year":"2001","unstructured":"G\u00f6ttlicher M.; Minucci S.; Zhu P.; Kr\u00e4mer O.H.; Schimpf A.; Giavara S.; Sleeman J.P.; Lo Coco F.; Nervi C.; Pelicci P.G.; Heinzel T.; Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001,20(24),6969-6978","journal-title":"EMBO J"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/med.20027","volume":"25","author":"Blaheta R.A.","year":"2005","unstructured":"Blaheta R.A.; Michaelis M.; Driever P.H.; Cinatl J.; Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 2005,25(4),383-397","journal-title":"Med Res Rev"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"A639","DOI":"10.1016\/j.jval.2014.08.2300","volume":"17","author":"Soto H.","year":"2014","unstructured":"Soto H.; Sanchez K.; Escobar J.Y.; Constanzo A.; Fernandez Z.; Melendez C.; Cost-effectiveness analysis of hydralazine and magnesium valproate LP associated with treatment for adult patients with metastatic recurrent or persistent cervical cancer in Mexico. Value Health 2014,17(7),A639","journal-title":"Value Health"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00277-010-1090-2","volume":"90","author":"Candelaria M.","year":"2011","unstructured":"Candelaria M.; Herrera A.; Labardini J.; Gonz\u00e1lez-Fierro A.; Trejo-Becerril C.; Taja-Chayeb L.; P\u00e9rez-C\u00e1rdenas E.; de la Cruz-Hern\u00e1ndez E.; Arias-Bofill D.; Vidal S.; Cervera E.; Due\u00f1as-Gonzalez A.; Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. Ann Hematol 2011,90(4),379-387","journal-title":"Ann Hematol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","volume":"110","author":"Soriano A.O.","year":"2007","unstructured":"Soriano A.O.; Yang H.; Faderl S.; Estrov Z.; Giles F.; Ravandi F.; Cortes J.; Wierda W.G.; Ouzounian S.; Quezada A.; Pierce S.; Estey E.H.; Issa J.P.; Kantarjian H.M.; Garcia-Manero G.; Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007,110(7),2302-2308","journal-title":"Blood"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1200\/JCO.2006.09.4169","volume":"25","author":"Blum W.","year":"2007","unstructured":"Blum W.; Klisovic R.B.; Hackanson B.; Liu Z.; Liu S.; Devine H.; Vukosavljevic T.; Huynh L.; Lozanski G.; Kefauver C.; Plass C.; Devine S.M.; Heerema N.A.; Murgo A.; Chan K.K.; Grever M.R.; Byrd J.C.; Marcucci G.; Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007,25(25),3884-3891","journal-title":"J Clin Oncol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1182\/blood.V112.11.3639.3639","volume":"112","author":"Kuendgen A.","year":"2008","unstructured":"Kuendgen A.; Bug G.; Ottmann O.G.; Haase D.; Hildebrandt B.; Habersang K.; Dienst A.; Haas R.; Germing U.; Gattermann N.; Treatment of poorrisk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacitidine and valproic acid. Blood 2008,112(11),3639","journal-title":"Blood"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1158\/1078-0432.CCR-09-0494","volume":"15","author":"Voso M.T.","year":"2009","unstructured":"Voso M.T.; Santini V.; Finelli C.; Musto P.; Pogliani E.; Angelucci E.; Fioritoni G.; Alimena G.; Maurillo L.; Cortelezzi A.; Buccisano F.; Gobbi M.; Borin L.; Di Tucci A.; Zini G.; Petti M.C.; Martinelli G.; Fabiani E.; Fazi P.; Vignetti M.; Piciocchi A.; Liso V.; Amadori S.; Leone G.; Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 2009,15(15),5002-5007","journal-title":"Clin Cancer Res"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"15855","DOI":"10.1038\/s41598-018-34193-1","volume":"8","author":"Taoka K.","year":"2018","unstructured":"Taoka K.; Arai S.; Kataoka K.; Hosoi M.; Miyauchi M.; Yamazaki S.; Honda A.; Aixinjueluo W.; Kobayashi T.; Kumano K.; Yoshimi A.; Otsu M.; Niwa A.; Nakahata T.; Nakauchi H.; Kurokawa M.; Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate. Sci Rep 2018,8(1),15855","journal-title":"Sci Rep"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/bjc.2014.95","volume":"110","author":"Huggett M.T.","year":"2014","unstructured":"Huggett M.T.; Jermyn M.; Gillams A.; Illing R.; Mosse S.; Novelli M.; Kent E.; Bown S.G.; Hasan T.; Pogue B.W.; Pereira S.P.; Phase I\/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer 2014,110(7),1698-1704","journal-title":"Br J Cancer"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10549-012-2146-x","volume":"135","author":"Lo V.C.","year":"2012","unstructured":"Lo V.C.; Akens M.K.; Moore S.; Yee A.J.; Wilson B.C.; Whyne C.M.; Beyond radiation therapy: photodynamic therapy maintains structural integrity of irradiated healthy and metastatically involved vertebrae in a pre-clinical in vivo model. Breast Cancer Res Treat 2012,135(2),391-401","journal-title":"Breast Cancer Res Treat"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"56241","DOI":"10.18632\/oncotarget.11025","volume":"7","author":"Morishita T.","year":"2016","unstructured":"Morishita T.; Hayakawa F.; Sugimoto K.; Iwase M.; Yamamoto H.; Hirano D.; Kojima Y.; Imoto N.; Naoe T.; Kiyoi H.; The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib. Oncotarget 2016,7(35),56241-56252","journal-title":"Oncotarget"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ccr.2006.09.006","volume":"10","author":"Wei G.","year":"2006","unstructured":"Wei G.; Twomey D.; Lamb J.; Schlis K.; Agarwal J.; Stam R.W.; Opferman J.T.; Sallan S.E.; den Boer M.L.; Pieters R.; Golub T.R.; Armstrong S.A.; Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006,10(4),331-342","journal-title":"Cancer Cell"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10528-015-9691-z","volume":"53","author":"Becerril J.L.","year":"2015","unstructured":"Becerril J.L.; Ben\u00edtez J.G.; Ju\u00e1rez J.J.; Ba\u00f1ales J.M.; Zer\u00f3n H.M.; Navarro M.D.; Evaluation of the effect of 1,3-Bis(4-Phenyl)-1H-1,2,3-triazolyl-2-propanolol on gene expression levels of JAK2-STAT3, NF-\u03baB, and SOCS3 in cells cultured from biopsies of mammary lesions. Biochem Genet 2015,53(11-12),291-300","journal-title":"Biochem Genet"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.bbi.2012.01.013","volume":"26","author":"Lamkin D.M.","year":"2012","unstructured":"Lamkin D.M.; Sloan E.K.; Patel A.J.; Chiang B.S.; Pimentel M.A.; Ma J.C.Y.; Arevalo J.M.; Morizono K.; Cole S.W.; Chronic stress enhances progression of acute lymphoblastic leukemia via \u03b2-adrenergic signaling. Brain Behav Immun 2012,26(4),635-641","journal-title":"Brain Behav Immun"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S1473-3099(07)70081-6","volume":"7","author":"Verdonck K.","year":"2007","unstructured":"Verdonck K.; Gonz\u00e1lez E.; Van Dooren S.; Vandamme A.M.; Vanham G.; Gotuzzo E.; Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007,7(4),266-281","journal-title":"Lancet Infect Dis"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/2211-5463.12055","volume":"6","author":"Kozako T.","year":"2016","unstructured":"Kozako T.; Soeda S.; Yoshimitsu M.; Arima N.; Kuroki A.; Hirata S.; Tanaka H.; Imakyure O.; Tone N.; Honda S.; Soeda S.; Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T-cell leukemia cells. FEBS Open Bio 2016,6(5),442-460","journal-title":"FEBS Open Bio"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-11-0047","volume":"10","author":"Yang Z.J.","year":"2011","unstructured":"Yang Z.J.; Chee C.E.; Huang S.; Sinicrope F.A.; The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 2011,10(9),1533-1541","journal-title":"Mol Cancer Ther"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.clml.2019.08.011","volume":"19","author":"Allegra A.","year":"2019","unstructured":"Allegra A.; Innao V.; Allegra A.G.; Leanza R.; Musolino C.; Selective inhibitors of nuclear export in the treatment of hematologic malignancies. Clin Lymphoma Myeloma Leuk 2019,19(11),689-698","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.pharmthera.2017.09.001","volume":"182","author":"Ettari R.","year":"2018","unstructured":"Ettari R.; Zappal\u00e0 M.; Grasso S.; Musolino C.; Innao V.; Allegra A.; Immunoproteasome-selective and non-selective inhibitors: a promising approach for the treatment of multiple myeloma. Pharmacol Ther 2018,182,176-192","journal-title":"Pharmacol Ther"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.leukres.2013.10.018","volume":"38","author":"Allegra A.","year":"2014","unstructured":"Allegra A.; Alonci A.; Gerace D.; Russo S.; Innao V.; Calabr\u00f2 L.; Musolino C.; New orally active proteasome inhibitors in multiple myeloma. Leuk Res 2014,38(1),1-9","journal-title":"Leuk Res"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/ejh.12107","volume":"90","author":"Allegra A.","year":"2013","unstructured":"Allegra A.; Penna G.; Alonci A.; Russo S.; Greve B.; Innao V.; Minardi V.; Musolino C.; Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. Eur J Haematol 2013,90(6),441-468","journal-title":"Eur J Haematol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1600-0609.2010.01558.x","volume":"86","author":"Allegra A.","year":"2011","unstructured":"Allegra A.; Sant\u2019antonio E.; Penna G.; Alonci A.; D\u2019Angelo A.; Russo S.; Cannav\u00f2 A.; Gerace D.; Musolino C.; Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors. Eur J Haematol 2011,86(2),93-110","journal-title":"Eur J Haematol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1128\/CMR.00078-09","volume":"23","author":"Kanoh S.","year":"2010","unstructured":"Kanoh S.; Rubin B.K.; Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010,23(3),590-615","journal-title":"Clin Microbiol Rev"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3332\/ecancer.2015.513","volume":"9","author":"Van Nuffel A.M.","year":"2015","unstructured":"Van Nuffel A.M.; Sukhatme V.; Pantziarka P.; Meheus L.; Sukhatme V.P.; Bouche G.; Repurposing drugs in oncology (ReDO)-clarithromycin as an anti-cancer agent. Ecancermedicalscience 2015,9,513","journal-title":"Ecancermedicalscience"},{"key":"ref=97","first-page":"815","volume":"37","author":"Nakamura M.","year":"2010","unstructured":"Nakamura M.; Kikukawa Y.; Takeya M.; Mitsuya H.; Hata H.; Clarithromycin attenuates autophagy in myeloma cells. Int J Oncol 2010,37(4),815-820","journal-title":"Int J Oncol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.3892\/ijo.2013.1870","volume":"42","author":"Moriya S.","year":"2013","unstructured":"Moriya S.; Che X.F.; Komatsu S.; Abe A.; Kawaguchi T.; Gotoh A.; Inazu M.; Tomoda A.; Miyazawa K.; Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells. Int J Oncol 2013,42(5),1541-1550","journal-title":"Int J Oncol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bbrc.2013.06.032","volume":"437","author":"Komatsu S.","year":"2013","unstructured":"Komatsu S.; Moriya S.; Che X.F.; Yokoyama T.; Kohno N.; Miyazawa K.; Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells. Biochem Biophys Res Commun 2013,437(1),41-47","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=100","author":"Durie B.G.","year":"1997","unstructured":"Durie B.G.; Villarete L.; Farvard A.; Ornopia M.; Urnovitz H.B.;   Clarithromycin (Biaxin) as primary treatment for myeloma. American Society of Hematologist. 579(suppl),1997"},{"key":"ref=101","first-page":"658","volume":"87","author":"Musto P.","year":"2002","unstructured":"Musto P.; Falcone A.; Sanpaolo G.; Bodenizza C.; Carotenuto M.; Carella A.M.; Inefficacy of clarithromycin in advanced multiple myeloma: a definitive report. Haematologica 2002,87(6),658-659","journal-title":"Haematologica"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1385\/MO:18:1:79","volume":"18","author":"Morris T.C.","year":"2001","unstructured":"Morris T.C.; Ranaghan L.; Morrison J.; Phase II trial of clarithromycin and pamidronate therapy in myeloma. Med Oncol Northern Ireland Regional Haematology Group2001,18(1),79-84","journal-title":"Med Oncol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/sj.leu.2401332","volume":"13","author":"Moreau P.","year":"1999","unstructured":"Moreau P.; Huynh A.; Facon T.; Bouilly I.; Sotto J.J.; Legros L.; Milpied N.; Attal M.; Bataille R.; Harousseau J.L.; Lack of efficacy of clarithromycin in advanced multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome (IFM). Leukemia 1999,13(3),490-491","journal-title":"Leukemia"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"237a","DOI":"10.1182\/blood-2002-09-2725","volume":"102","author":"Niesvizky R.","year":"2003","unstructured":"Niesvizky R.; Dexamethasone alone, or in combination with low-dose thalidomide as induction therapy for advanced multiple myeloma, and the effect of the addition of clarithromycin on response rate. Interim results of a prospective, sequential, randomized Trial. Blood 2003,102(11),237a","journal-title":"Blood"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1365-2141.2008.07360.x","volume":"143","author":"Morris T.C.","year":"2008","unstructured":"Morris T.C.; Kettle P.J.; Drake M.; Jones F.C.; Hull D.R.; Boyd K.; Morrison A.; Clarke P.; O\u2019Reilly P.; Quinn J.; Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed\/refractory myeloma. Br J Haematol 2008,143(3),349-354","journal-title":"Br J Haematol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1053\/j.seminoncol.2005.06.018","volume":"32","author":"Knight R.","year":"2005","unstructured":"Knight R.; IMiDs: a novel class of immunomodulators. Semin Oncol 2005,32(4)(Suppl. 5),S24-S30","journal-title":"Semin Oncol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1182\/blood-2007-05-090258","volume":"111","author":"Niesvizky R.","year":"2008","unstructured":"Niesvizky R.; Jayabalan D.S.; Christos P.J.; Furst J.R.; Naib T.; Ely S.; Jalbrzikowski J.; Pearse R.N.; Zafar F.; Pekle K.; Larow A.; Lent R.; Mark T.; Cho H.J.; Shore T.; Tepler J.; Harpel J.; Schuster M.W.; Mathew S.; Leonard J.P.; Mazumdar M.; Chen-Kiang S.; Coleman M.; BiRD (Biaxin [clarithromycin]\/Revlimid [lenalidomide]\/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008,111(3),1101-1109","journal-title":"Blood"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1182\/blood-2012-08-448563","volume":"121","author":"Rossi A.","year":"2013","unstructured":"Rossi A.; Mark T.; Jayabalan D.; Christos P.; Zafar F.; Pekle K.; Pearse R.; Chen-Kiang S.; Coleman M.; Niesvizky R.; BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood 2013,121(11),1982-1985","journal-title":"Blood"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","volume":"106","author":"Rajkumar S.V.","year":"2005","unstructured":"Rajkumar S.V.; Hayman S.R.; Lacy M.Q.; Dispenzieri A.; Geyer S.M.; Kabat B.; Zeldenrust S.R.; Kumar S.; Greipp P.R.; Fonseca R.; Lust J.A.; Russell S.J.; Kyle R.A.; Witzig T.E.; Gertz M.A.; Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma. Blood 2005,106(13),4050-4053","journal-title":"Blood"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"Rajkumar S.V.","year":"2010","unstructured":"Rajkumar S.V.; Jacobus S.; Callander N.S.; Fonseca R.; Vesole D.H.; Williams M.E.; Abonour R.; Siegel D.S.; Katz M.; Greipp P.R.; Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol Eastern Cooperative Oncology Group2010,11(1),29-37","journal-title":"Lancet Oncol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ajh.21777","volume":"85","author":"Gay F.","year":"2010","unstructured":"Gay F.; Rajkumar S.V.; Coleman M.; Kumar S.; Mark T.; Dispenzieri A.; Pearse R.; Gertz M.A.; Leonard J.; Lacy M.Q.; Chen-Kiang S.; Roy V.; Jayabalan D.S.; Lust J.A.; Witzig T.E.; Fonseca R.; Kyle R.A.; Greipp P.R.; Stewart A.K.; Niesvizky R.; Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol 2010,85(9),664-669","journal-title":"Am J Hematol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s00277-013-1761-x","volume":"92","author":"Kato H.","year":"2013","unstructured":"Kato H.; Onishi Y.; Okitsu Y.; Katsuoka Y.; Fujiwara T.; Fukuhara N.; Ishizawa K.; Takagawa M.; Harigae H.; Addition of clarithromycin to lenalidomide\/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide. Ann Hematol 2013,92(12),1711-1712","journal-title":"Ann Hematol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"E116","DOI":"10.1002\/ajh.23733","volume":"89","author":"Ghosh N.","year":"2014","unstructured":"Ghosh N.; Tucker N.; Zahurak M.; Wozney J.; Borrello I.; Huff C.A.; Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma. Am J Hematol 2014,89(8),E116-E120","journal-title":"Am J Hematol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.3109\/10428194.2014.896005","volume":"55","author":"Mark T.M.","year":"2014","unstructured":"Mark T.M.; Bowman I.A.; Rossi A.C.; Shah M.; Rodriguez M.; Quinn R.; Pearse R.N.; Zafar F.; Pekle K.; Jayabalan D.; Ely S.; Coleman M.; Chen-Kiang S.; Niesvizky R.; Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. Leuk Lymphoma 2014,55(12),2842-2849","journal-title":"Leuk Lymphoma"},{"key":"ref=115","doi-asserted-by":"publisher","author":"Rossi A.C.","unstructured":"Rossi A.C.; Mark T.M.; Rodriguez M.; Shah M.; Quinn R.; Pearse R.N.; Zafar F.; Pekle K.; Speaker S.; Jayabalan D.; Ely S.;  Clarithromycin, pomalidomide, and dexamethasone (ClaPD) in relapsed or refractory multiple myeloma. J. Clinical Oncol., 2012, 30(15_suppl), 8036-8036.","DOI":"10.1200\/jco.2012.30.15_suppl.8036"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"11401","DOI":"10.1038\/s41598-017-11924-4","volume":"7","author":"Salentin S.","year":"2017","unstructured":"Salentin S.; Adasme M.F.; Heinrich J.C.; Haupt V.J.; Daminelli S.; Zhang Y.; Schroeder M.; From malaria to cancer: computational drug repositioning of amodiaquine using PLIP interaction patterns. Sci Rep 2017,7(1),11401","journal-title":"Sci Rep"},{"key":"ref=117","unstructured":"LiverTox: clinical and research information on drug-induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases, 2012."},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.3892\/or.2020.7562","volume":"43","author":"Allegra A.","year":"2020","unstructured":"Allegra A.; Innao V.; Allegra A.G.; Pulvirenti N.; Pugliese M.; Musolino C.; Antitumorigenic action of nelfinavir: effects on multiple myeloma and hematologic malignancies.(Review) Oncol Rep 2020,43(6),1729-1736","journal-title":"Oncol Rep"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1535-7163.473.3.4","volume":"3","author":"Ikezoe T.","year":"2004","unstructured":"Ikezoe T.; Saito T.; Bandobashi K.; Yang Y.; Koeffler H.P.; Taguchi H.; HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1\/2. Mol Cancer Ther 2004,3(4),473-479","journal-title":"Mol Cancer Ther"},{"key":"ref=120","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.87","volume":"3","author":"Kawabata S.","year":"2012","unstructured":"Kawabata S.; Gills J.J.; Mercado-Matos J.R.; Lopiccolo J.; Wilson W.; Hollander M.C.; Dennis P.A.; Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. Cell Death Dis 2012,3(7)","journal-title":"Cell Death Dis"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","volume":"24","author":"Leung-Hagesteijn C.","year":"2013","unstructured":"Leung-Hagesteijn C.; Erdmann N.; Cheung G.; Keats J.J.; Stewart A.K.; Reece D.E.; Chung K.C.; Tiedemann R.E.; Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 2013,24(3),289-304","journal-title":"Cancer Cell"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/ncb2412","volume":"14","author":"Mayor T.","year":"2011","unstructured":"Mayor T.; Navigating the ERAD interaction network. Nat Cell Biol 2011,14(1),46-47","journal-title":"Nat Cell Biol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"Obeng E.A.","year":"2006","unstructured":"Obeng E.A.; Carlson L.M.; Gutman D.M.; Harrington W.J.; Jr.; Lee, K.P.; Boise, L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006,107(12),4907-4916","journal-title":"Blood"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3324\/haematol.2011.043331","volume":"97","author":"Ling S.C.","year":"2012","unstructured":"Ling S.C.; Lau E.K.; Al-Shabeeb A.; Nikolic A.; Catalano A.; Iland H.; Horvath N.; Ho P.J.; Harrison S.; Fleming S.; Joshua D.E.; Allen J.D.; Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica 2012,97(1),64-72","journal-title":"Haematologica"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/35085509","volume":"412","author":"Reimold A.M.","year":"2001","unstructured":"Reimold A.M.; Iwakoshi N.N.; Manis J.; Vallabhajosyula P.; Szomolanyi-Tsuda E.; Gravallese E.M.; Friend D.; Grusby M.J.; Alt F.; Glimcher L.H.; Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001,412(6844),300-307","journal-title":"Nature"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1182\/blood-2010-08-303099","volume":"117","author":"Papandreou I.","year":"2011","unstructured":"Papandreou I.; Denko N.C.; Olson M.; Van Melckebeke H.; Lust S.; Tam A.; Solow-Cordero D.E.; Bouley D.M.; Offner F.; Niwa M.; Koong A.C.; Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood 2011,117(4),1311-1314","journal-title":"Blood"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1470-2045(08)70334-6","volume":"10","author":"Chow W.A.","year":"2009","unstructured":"Chow W.A.; Jiang C.; Guan M.; Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol 2009,10(1),61-71","journal-title":"Lancet Oncol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1158\/1078-0432.CCR-10-3216","volume":"17","author":"Guan M.","year":"2011","unstructured":"Guan M.; Fousek K.; Jiang C.; Guo S.; Synold T.; Xi B.; Shih C.C.; Chow W.A.; Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6. Clin Cancer Res 2011,17(7),1796-1806","journal-title":"Clin Cancer Res"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1038\/sj.bjc.6603435","volume":"95","author":"Yang Y.","year":"2006","unstructured":"Yang Y.; Ikezoe T.; Nishioka C.; Bandobashi K.; Takeuchi T.; Adachi Y.; Kobayashi M.; Takeuchi S.; Koeffler H.P.; Taguchi H.; NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines. Br J Cancer 2006,95(12),1653-1662","journal-title":"Br J Cancer"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3324\/haematol.2011.049981","volume":"97","author":"Bono C.","year":"2012","unstructured":"Bono C.; Karlin L.; Harel S.; Mouly E.; Labaume S.; Galicier L.; Apcher S.; Sauvageon H.; Fermand J.P.; Bories J.C.; Arnulf B.; The HIV-1 protease inhibitor nelfinavir impairs protea-some activity and inhibits the multiple myeloma cells proliferation in vitro and in vivo. Haematologica 2012,97(7),1101-1109","journal-title":"Haematologica"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3324\/haematol.2015.135780","volume":"101","author":"Driessen C.","year":"2016","unstructured":"Driessen C.; Kraus M.; Joerger M.; Rosing H.; Bader J.; Hitz F.; Berset C.; Xyrafas A.; Hawle H.; Berthod G.; Overkleeft H.S.; Sessa C.; Huitema A.; Pabst T.; von Moos R.; Hess D.; Mey U.J.; Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65\/08). Haematologica 2016,101(3),346-355","journal-title":"Haematologica"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1182\/blood-2018-05-851170","volume":"132","author":"Driessen C.","year":"2018","unstructured":"Driessen C.; M\u00fcller R.; Novak U.; Cantoni N.; Betticher D.; Mach N.; R\u00fcfer A.; Mey U.; Samaras P.; Ribi K.; Besse L.; Besse A.; Berset C.; Rondeau S.; Hawle H.; Hitz F.; Pabst T.; Zander T.; Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma. Blood 2018,132(19),2097-2100","journal-title":"Blood"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/nm.2471","volume":"17","author":"Tu Y.","year":"2011","unstructured":"Tu Y.; The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med 2011,17(10),1217-1220","journal-title":"Nat Med"},{"key":"ref=134","year":"2006","unstructured":"Guidelines for the Treatment of Malaria World Health Organization2006","journal-title":"Guidelines for the Treatment of Malaria"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3892\/ijo.18.4.767","volume":"18","author":"Efferth T.","year":"2001","unstructured":"Efferth T.; Dunstan H.; Sauerbrey A.; Miyachi H.; Chitambar C.R.; The anti-malarial artesunate is also active against cancer. Int J Oncol 2001,18(4),767-773","journal-title":"Int J Oncol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1124\/mol.64.2.382","volume":"64","author":"Efferth T.","year":"2003","unstructured":"Efferth T.; Sauerbrey A.; Olbrich A.; Gebhart E.; Rauch P.; Weber H.O.; Hengstler J.G.; Halatsch M.E.; Volm M.; Tew K.D.; Ross D.D.; Funk J.O.; Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 2003,64(2),382-394","journal-title":"Mol Pharmacol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3892\/ijo.23.4.1231","volume":"23","author":"Efferth T.","year":"2003","unstructured":"Efferth T.; Briehl M.M.; Tome M.E.; Role of antioxidant genes for the activity of artesunate against tumor cells. Int J Oncol 2003,23(4),1231-1235","journal-title":"Int J Oncol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/ejh.12176","volume":"91","author":"Holien T.","year":"2013","unstructured":"Holien T.; Olsen O.E.; Misund K.; Hella H.; Waage A.; R\u00f8 T.B.; Sundan A.; Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate. Eur J Haematol 2013,91(4),339-346","journal-title":"Eur J Haematol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s11655-019-3207-3","volume":"26","author":"Li Y.","year":"2020","unstructured":"Li Y.; Shan N.N.; Sui X.H.; Research progress on artemisinin and its derivatives against hematological malignancies. Chin J Integr Med 2020,26(12),947-955","journal-title":"Chin J Integr Med"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s12185-010-0697-3","volume":"92","author":"Chen H.","year":"2010","unstructured":"Chen H.; Shi L.; Yang X.; Li S.; Guo X.; Pan L.; Artesunate inhibiting angiogenesis induced by human myeloma RPMI8226 cells. Int J Hematol 2010,92(4),587-597","journal-title":"Int J Hematol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1128\/AAC.45.1.181-186.2001","volume":"45","author":"Davis T.M.","year":"2001","unstructured":"Davis T.M.; Phuong H.L.; Ilett K.F.; Hung N.C.; Batty K.T.; Phuong V.D.; Powell S.M.; Thien H.V.; Binh T.Q.; Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria. Antimicrob Agents Chemother 2001,45(1),181-186","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.drup.2004.07.001","volume":"7","author":"Krishna S.","year":"2004","unstructured":"Krishna S.; Uhlemann A.C.; Haynes R.K.; Artemisinins: mechanisms of action and potential for resistance. Drug Resist Updat 2004,7(4-5),233-244","journal-title":"Drug Resist Updat"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1080\/14786419.2018.1483927","volume":"33","author":"Ettari R.","year":"2019","unstructured":"Ettari R.; Previti S.; Maiorana S.; Allegra A.; Schirmeister T.; Grasso S.; Zappal\u00e0 M.; Drug combination studies of curcumin and genistein against rhodesain of Trypanosoma brucei rhodesiense. Nat Prod Res 2019,33(24),3577-3581","journal-title":"Nat Prod Res"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"10639","DOI":"10.1021\/jf1016303","volume":"58","author":"Huang T.Y.","year":"2010","unstructured":"Huang T.Y.; Tsai T.H.; Hsu C.W.; Hsu Y.C.; Curcuminoids suppress the growth and induce apoptosis through caspase-3-dependent pathways in glioblastoma multiforme (GBM) 8401 cells. J Agric Food Chem 2010,58(19),10639-10645","journal-title":"J Agric Food Chem"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1182\/blood-2002-05-1320","volume":"101","author":"Bharti A.C.","year":"2003","unstructured":"Bharti A.C.; Donato N.; Singh S.; Aggarwal B.B.; Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003,101(3),1053-1062","journal-title":"Blood"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"5940","DOI":"10.4049\/jimmunol.172.10.5940","volume":"172","author":"Bharti A.C.","year":"2004","unstructured":"Bharti A.C.; Takada Y.; Aggarwal B.B.; Curcumin (diferuloylmethane) inhibits receptor activator of NF-\u03ba B ligand-induced NF-\u03ba B activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol 2004,172(10),5940-5947","journal-title":"J Immunol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ajh.23159","volume":"87","author":"Golombick T.","year":"2012","unstructured":"Golombick T.; Diamond T.H.; Manoharan A.; Ramakrishna R.; Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study. Am J Hematol 2012,87(5),455-460","journal-title":"Am J Hematol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2174\/138920308784533998","volume":"9","author":"Yang H.","year":"2008","unstructured":"Yang H.; Landis-Piwowar K.R.; Chen D.; Milacic V.; Dou Q.P.; Natural compounds with proteasome inhibitory activity for cancer prevention and treatment. Curr Protein Pept Sci 2008,9(3),227-239","journal-title":"Curr Protein Pept Sci"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"7283","DOI":"10.1158\/0008-5472.CAN-07-6246","volume":"68","author":"Milacic V.","year":"2008","unstructured":"Milacic V.; Banerjee S.; Landis-Piwowar K.R.; Sarkar F.H.; Majumdar A.P.; Dou Q.P.; Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res 2008,68(18),7283-7292","journal-title":"Cancer Res"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3892\/ijmm_00000484]","volume":"26","author":"Wan S.B.","year":"2010","unstructured":"Wan S.B.; Yang H.; Zhou Z.; Cui Q.C.; Chen D.; Kanwar J.; Mohammad I.; Dou Q.P.; Chan T.H.; Evaluation of curcumin acetates and amino acid conjugates as proteasome inhibitors. Int J Mol Med 2010,26(4),447-455","journal-title":"Int J Mol Med"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3892\/ijmm.2011.814]","volume":"29","author":"Mujtaba T.","year":"2012","unstructured":"Mujtaba T.; Kanwar J.; Wan S.B.; Chan T.H.; Dou Q.P.; Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs. Int J Mol Med 2012,29(1),102-106","journal-title":"Int J Mol Med"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.molonc.2008.09.006","volume":"2","author":"Park J.","year":"2008","unstructured":"Park J.; Ayyappan V.; Bae E.K.; Lee C.; Kim B.S.; Kim B.K.; Lee Y.Y.; Ahn K.S.; Yoon S.S.; Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. Mol Oncol 2008,2(4),317-326","journal-title":"Mol Oncol"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1158\/1535-7163.MCT-08-0905","volume":"8","author":"Sung B.","year":"2009","unstructured":"Sung B.; Kunnumakkara A.B.; Sethi G.; Anand P.; Guha S.; Aggarwal B.B.; Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 2009,8(4),959-970","journal-title":"Mol Cancer Ther"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.tiv.2017.12.001","volume":"47","author":"Allegra A.","year":"2018","unstructured":"Allegra A.; Speciale A.; Molonia M.S.; Guglielmo L.; Musolino C.; Ferlazzo G.; Costa G.; Saija A.; Cimino F.; Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-\u03baB pathways. Toxicol In Vitro 2018,47,186-194","journal-title":"Toxicol In Vitro"},{"key":"ref=155","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111715","volume":"183","author":"Catalano R.","year":"2019","unstructured":"Catalano R.; Rocca R.; Juli G.; Costa G.; Maruca A.; Artese A.; Caracciolo D.; Tagliaferri P.; Alcaro S.; Tassone P.; Amodio N.; A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. Eur J Med Chem 2019,183","journal-title":"Eur J Med Chem"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1476-9255-7-41","volume":"7","author":"Meyer D.M.","year":"2010","unstructured":"Meyer D.M.; Jesson M.I.; Li X.; Elrick M.M.; Funckes-Shippy C.L.; Warner J.D.; Gross C.J.; Dowty M.E.; Ramaiah S.K.; Hirsch J.L.; Saabye M.J.; Barks J.L.; Kishore N.; Morris D.L.; Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010,7,41","journal-title":"J Inflamm (Lond)"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/nri1226","volume":"3","author":"Shuai K.","year":"2003","unstructured":"Shuai K.; Liu B.; Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003,3(11),900-911","journal-title":"Nat Rev Immunol"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.3390\/ijms20112822","volume":"20","author":"Allegra A.","year":"2019","unstructured":"Allegra A.; Innao V.; Allegra A.G.; Pugliese M.; Di Salvo E.; Ventura-Spagnolo E.; Musolino C.; Gangemi S.; Lymphocyte subsets and inflammatory cytokines of monoclonal gammopathy of undetermined significance and multiple myeloma. Int J Mol Sci 2019,20(11),2822","journal-title":"Int J Mol Sci"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3324\/haematol.2017.174482","volume":"103","author":"Lam C.","year":"2018","unstructured":"Lam C.; Ferguson I.D.; Mariano M.C.; Lin Y.T.; Murnane M.; Liu H.; Smith G.A.; Wong S.W.; Taunton J.; Liu J.O.; Mitsiades C.S.; Hann B.C.; Aftab B.T.; Wiita A.P.; Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 2018,103(7),1218-1228","journal-title":"Haematologica"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1053\/sonc.2003.50079","volume":"30","author":"Dimopoulos M.A.","year":"2003","unstructured":"Dimopoulos M.A.; Tsatalas C.; Zomas A.; Hamilos G.; Panayiotidis P.; Margaritis D.; Matsouka C.; Economopoulos T.; Anagnostopoulos N.; Treatment of Waldenstrom\u2019s macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol 2003,30(2),265-269","journal-title":"Semin Oncol"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1053\/sonc.2003.50044","volume":"30","author":"Coleman M.","year":"2003","unstructured":"Coleman M.; Leonard J.; Lyons L.; Szelenyi H.; Niesvizky R.; Treatment of Waldenstrom\u2019s macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin Oncol 2003,30(2),270-274","journal-title":"Semin Oncol"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3109\/10428194.2012.698737","volume":"54","author":"Schafranek L.","year":"2013","unstructured":"Schafranek L.; Leclercq T.M.; White D.L.; Hughes T.P.; Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy. Leuk Lymphoma 2013,54(1),198-201","journal-title":"Leuk Lymphoma"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3109\/10428194.2012.656105","volume":"53","author":"Carella A.M.","year":"2012","unstructured":"Carella A.M.; Beltrami G.; Pica G.; Carella A.; Catania G.; Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia. Leuk Lymphoma 2012,53(7),1409-1411","journal-title":"Leuk Lymphoma"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1080\/07391102.2016.1196462","volume":"35","author":"Singh V.K.","year":"2017","unstructured":"Singh V.K.; Chang H.H.; Kuo C.C.; Shiao H.Y.; Hsieh H.P.; Coumar M.S.; Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors. J Biomol Struct Dyn 2017,35(8),1833-1848","journal-title":"J Biomol Struct Dyn"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1517\/13543784.2011.546344","volume":"20","author":"Barouch-Bentov R.","year":"2011","unstructured":"Barouch-Bentov R.; Sauer K.; Mechanisms of drug resistance in kinases. Expert Opin Investig Drugs 2011,20(2),153-208","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/leu.2010.238","volume":"25","author":"Bixby D.","year":"2011","unstructured":"Bixby D.; Talpaz M.; Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011,25(1),7-22","journal-title":"Leukemia"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jmgm.2017.04.005","volume":"74","author":"Sohraby F.","year":"2017","unstructured":"Sohraby F.; Bagheri M.; Aliyar M.; Aryapour H.; In silico drug repurposing of FDA-approved drugs to predict new inhibitors for drug resistant T315I mutant and wild-type BCR-ABL1: a virtual screening and molecular dynamics study. J Mol Graph Model 2017,74,234-240","journal-title":"J Mol Graph Model"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature14119","volume":"519","author":"Pemovska T.","year":"2015","unstructured":"Pemovska T.; Johnson E.; Kontro M.; Repasky G.A.; Chen J.; Wells P.; Cronin C.N.; McTigue M.; Kallioniemi O.; Porkka K.; Murray B.W.; Wennerberg K.; Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature 2015,519(7541),102-105","journal-title":"Nature"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1182\/blood-2012-01-404194","volume":"119","author":"Kuo S.H.","year":"2012","unstructured":"Kuo S.H.; Yeh K.H.; Wu M.S.; Lin C.W.; Hsu P.N.; Wang H.P.; Chen L.T.; Cheng A.L.; Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas. Blood 2012,119(21),4838-4844","journal-title":"Blood"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1182\/blood-2012-06-438424","volume":"120","author":"Ferreri A.J.","year":"2012","unstructured":"Ferreri A.J.; Govi S.; Raderer M.; Mul\u00e8 A.; Andriani A.; Caracciolo D.; Devizzi L.; Ilariucci F.; Luminari S.; Viale E.; M\u00fcllauer L.; Dell\u2019Oro S.; Arcidiacono P.G.; Ponzoni M.; Patti C.; Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. Blood 2012,120(18),3858-3860","journal-title":"Blood"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/00365520500331224","volume":"41","author":"Ochi M.","year":"2006","unstructured":"Ochi M.; Tominaga K.; Okazaki H.; Yamamori K.; Wada T.; Shiba M.; Sasaki E.; Watanabe T.; Fujiwara Y.; Oshitani N.; Higuchi K.; Arakawa T.; Regression of primary low-grade mucosa-associated lymphoid tissue lymphoma of duodenum after long-term treatment with clarithromycin. Scand J Gastroenterol 2006,41(3),365-369","journal-title":"Scand J Gastroenterol"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1365-2141.2010.08179.x","volume":"150","author":"Govi S.","year":"2010","unstructured":"Govi S.; Dognini G.P.; Licata G.; Crocchiolo R.; Resti A.G.; Ponzoni M.; Ferreri A.J.; Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. Br J Haematol 2010,150(2),226-229","journal-title":"Br J Haematol"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1378\/chest.09-2358","volume":"138","author":"Ishimatsu Y.","year":"2010","unstructured":"Ishimatsu Y.; Mukae H.; Matsumoto K.; Harada T.; Hara A.; Hara S.; Amenomori M.; Fujita H.; Sakamoto N.; Hayashi T.; Kohno S.; Two cases with pulmonary mucosa-associated lymphoid tissue lymphoma successfully treated with clarithromycin. Chest 2010,138(3),730-733","journal-title":"Chest"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867327999200817102154","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/184874\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867327999200817102154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T18:31:13Z","timestamp":1660069873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/184874\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":173,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867327999200817102154","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-05-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}